| Symbol | BMEA |
|---|---|
| Name | BIOMEA FUSION, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 900 MIDDLEFIELD ROAD,4TH FLOOR, REDWOOD CITY, California, 94063, United States |
| Telephone | +1 650 980-9099 |
| Fax | — |
| — | |
| Website | https://www.biomeafusion.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companys lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Additional info from NASDAQ: |
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
Read moreNew Form DEF 14A - Biomea Fusion, Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001193125-26-182080 <b>Size:</b> 2 MB
Read moreNew Form ARS - Biomea Fusion, Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001193125-26-182038 <b>Size:</b> 1 MB
Read moreErdtmann Rainer M 🟢 acquired 452.5K shares (1 derivative) of Biomea Fusion, Inc. (BMEA) at $1.49 Transaction Date: Apr 01, 2026 | Filing ID: 142178
Read moreHitchcock Michael J.M. 🟢 acquired 667.5K shares (1 derivative) of Biomea Fusion, Inc. (BMEA) at $1.49 Transaction Date: Apr 01, 2026 | Filing ID: 142177
Read moreBiomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies
Read more(10% Negative) BIOMEA FUSION, INC. (BMEA) Announces Delay in data Trials for type 2 diabetes from which we expect Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review
Read moreBiomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
Read moreBiomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07502508 | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who A… | Phase2 | Type 2 Diabetes | Recruiting | 2026-04-01 | 2027-07-01 | ClinicalTrials.gov |
| NCT07502495 | Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Ac… | Phase2 | Type 2 Diabetes | Recruiting | 2026-03-27 | 2027-07-01 | ClinicalTrials.gov |
| NCT07223216 | Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants | Phase1 | Obesity | Active_Not_Recruiting | 2025-10-23 | 2026-06-01 | ClinicalTrials.gov |
| NCT07254286 | Food Effect Study in Healthy Volunteers | Phase1 | Healthy Volunteer | Completed | 2025-09-11 | 2026-01-14 | ClinicalTrials.gov |
| NCT06152042 | Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus | Phase2 | Type 1 Diabetes Mellitus | Terminated | 2023-12-28 | 2025-07-18 | ClinicalTrials.gov |
| NCT05918692 | A Phase 1 Study of BMF-500 in Adults With Acute Leukemia | Phase1 | Acute Myeloid Leukemia | Active_Not_Recruiting | 2023-07-26 | 2026-04-01 | ClinicalTrials.gov |
| NCT05631574 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven No… | Phase1 | Non Small Cell Lung Cancer | Terminated | 2023-01-12 | 2025-01-15 | ClinicalTrials.gov |
| NCT05731544 | Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Di… | Phase1 | Type 2 Diabetes Mellitus | Completed | 2022-08-17 | 2025-07-08 | ClinicalTrials.gov |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (… | Phase1 | Acute Myeloid Leukemia | Terminated | 2022-01-24 | 2025-05-02 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| icovamenib 100 mg | DRUG | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502508 |
| Placebo | DRUG | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| icovamenib 100mg | DRUG | Phase PHASE2 | Type 2 Diabetes | RECRUITING | NCT07502495 |
| Icovamenib HPMC | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07254286 |
| Icovamenib | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT07254286 |
| BMF-650 | DRUG | Phase PHASE1 | Obesity | RECRUITING | NCT07223216 |
| BMF-500 | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | ACTIVE_NOT_RECRUITING | NCT05918692 |
| BMF-219 | DRUG | Phase PHASE2 | Type 1 Diabetes Mellitus | TERMINATED | NCT06152042 |